EP3934640A4 - Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease - Google Patents

Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease Download PDF

Info

Publication number
EP3934640A4
EP3934640A4 EP20766948.2A EP20766948A EP3934640A4 EP 3934640 A4 EP3934640 A4 EP 3934640A4 EP 20766948 A EP20766948 A EP 20766948A EP 3934640 A4 EP3934640 A4 EP 3934640A4
Authority
EP
European Patent Office
Prior art keywords
composition
liver disease
fatty liver
treating fatty
monoacetyldiacylglycerol compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20766948.2A
Other languages
German (de)
French (fr)
Other versions
EP3934640A1 (en
Inventor
Ki Young SOHN
Jae Wha Kim
Sun Young Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzychem Lifesciences Corp
Original Assignee
Enzychem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190086967A external-priority patent/KR102218545B1/en
Application filed by Enzychem Lifesciences Corp filed Critical Enzychem Lifesciences Corp
Priority claimed from PCT/IB2020/051990 external-priority patent/WO2020178803A1/en
Publication of EP3934640A1 publication Critical patent/EP3934640A1/en
Publication of EP3934640A4 publication Critical patent/EP3934640A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20766948.2A 2019-03-07 2020-03-06 Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease Withdrawn EP3934640A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190026326 2019-03-07
KR1020190086967A KR102218545B1 (en) 2019-03-07 2019-07-18 A composition for treating fatty liver disease comprising monoacetyldiacylglycerol compound as an active ingredient
US201962908392P 2019-09-30 2019-09-30
PCT/IB2020/051990 WO2020178803A1 (en) 2019-03-07 2020-03-06 Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease

Publications (2)

Publication Number Publication Date
EP3934640A1 EP3934640A1 (en) 2022-01-12
EP3934640A4 true EP3934640A4 (en) 2022-12-07

Family

ID=76446703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20766948.2A Withdrawn EP3934640A4 (en) 2019-03-07 2020-03-06 Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease

Country Status (4)

Country Link
EP (1) EP3934640A4 (en)
JP (1) JP2022523464A (en)
CN (1) CN113194940A (en)
AU (1) AU2020231261A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037090A1 (en) * 2013-08-19 2016-06-29 Enzychem Lifesciences Corporation Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating rheumatoid arthritis
WO2018070854A2 (en) * 2016-10-13 2018-04-19 주식회사 엔지켐생명과학 Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037091B1 (en) * 2013-08-19 2021-10-06 Enzychem Lifesciences Corporation Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037090A1 (en) * 2013-08-19 2016-06-29 Enzychem Lifesciences Corporation Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating rheumatoid arthritis
WO2018070854A2 (en) * 2016-10-13 2018-04-19 주식회사 엔지켐생명과학 Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Abstracts 1 to 258", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 44, 25 September 2006 (2006-09-25), pages 188A - 286A, XP071560995, ISSN: 0270-9139, DOI: 10.1002/HEP.21395 *
KIM MYUNG-HWAN ET AL: "EC-18, A Novel Immune Resolution Accelerator, Improves Nash and Liver Fibrosis", HEPATOLOGY; 70TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES (AASLD) / LIVER MEETING; BOSTON, MA, USA; NOVEMBER 08 -12, 2019, JOHN WILEY & SONS, INC, US, vol. 70, no. Suppl. 1, 1 October 2019 (2019-10-01), pages 1258A - 1259A, XP009540056, ISSN: 0270-9139 *
See also references of WO2020178803A1 *

Also Published As

Publication number Publication date
JP2022523464A (en) 2022-04-25
CN113194940A (en) 2021-07-30
EP3934640A1 (en) 2022-01-12
AU2020231261A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP3934652A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3890725A4 (en) Compositions for treating dermatological diseases
EP3915583A4 (en) Combined pharmaceutical composition for treating tumor
EP3838937A4 (en) Photopolymer composition
EP3685840A4 (en) Compound pharmaceutical composition for treating inflammatory skin diseases
EP3852753A4 (en) Treatment for non-alcoholic fatty liver disease
EP4013853A4 (en) Improved methods for making organoid compositions
EP4045094A4 (en) Compositions and methods for treating liver disease
EP3653219A4 (en) Composition for treating fatty liver
EP3933030A4 (en) Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103
EP3760055A4 (en) Composition for inhibiting fat accumulation
EP3970745A4 (en) Pharmaceutical composition for treating tumor
EP3866852A4 (en) Compositions and methods for treatment of liver disease
EP3890719A4 (en) Very long chain fatty acid compositions
EP3824296A4 (en) Liver disease
EP3974026A4 (en) Composition for improving liver function
EP3781158A4 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
EP3911329A4 (en) Composition for preventing or treating metabolic liver disease
EP4031130A4 (en) Compositions for the treatment of solid tumors
EP3927375A4 (en) Compositions for disease treatment
EP3958892A4 (en) Methods of treating liver disease
EP3873457A4 (en) Novel compounds useful for treating cardiovascular diseases
EP3760293A4 (en) Composition for removing sulfur-containing compound
EP3766363A4 (en) Composition for improving skin conditions
EP3701953A4 (en) Composition for preventing or alleviating nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031230000

Ipc: A61K0031231000

A4 Supplementary search report drawn up and despatched

Effective date: 20221107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20221031BHEP

Ipc: A23L 33/115 20160101ALI20221031BHEP

Ipc: A61K 45/06 20060101ALI20221031BHEP

Ipc: A61K 31/231 20060101AFI20221031BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230606